FDA Expands Indications for Lutetium Lu 177 Vipivotide Tetraxetan to Include Patients with PSMA Positive mCRPC By Ogkologos - April 25, 2025 681 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the PSMAfore study Source RELATED ARTICLESMORE FROM AUTHOR Solid Organ Transplant Recipients with Pretransplant Cancer Have an Elevated Risk of Posttransplant Cancer of the Same Cancer Type Population-based lung cancer screening can reduce mortality in people who have never smoked, study shows in China EMA Recommends Granting a Conditional Marketing Authorisation for Tovorafenib MOST POPULAR Survey Shows Oncologists Underestimate How Many Cancer Patients Use Alternative Therapies June 16, 2021 ESMO Targeted Anticancer Therapies Congress 2024, 26-28 February, Paris, France February 20, 2024 The most important cancer research stories of 2022 December 14, 2022 Marine Runs Five Marathons in Five Days to Help Fund Sister’s... April 20, 2021 Load more HOT NEWS What to Know About At-Home DNA Tests for Detecting Cancer Risk Doctors Want Breast Cancer Warning Label Put On Cheese CCDI Activities Enhance NCI’s Childhood and AYA Cancer Research How to Safely Keep Up With Your Cancer Screening and Care...
